Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
HCW Biologics secured U.S. patent protection for HCW9302, an IL-2-based immunotherapeutic designed to expand regulatory T cells in alopecia areata. Early Phase 1 data show positive responses after single-dose treatment with no dose-limiting toxicities, positioning the candidate for continued development through 2026.
Rapalogix Health established a dedicated research laboratory at Princeton Innovation Center to advance translational research on rapalogs, proprietary compounds designed to modulate longevity pathways in skin. The facility enables systematic investigation of mechanism of action, formulation optimization, and biomarker development for next-generation skin longevity products.
China's regulatory approval of lecanemab's subcutaneous formulation expands access to an amyloid-targeting monoclonal antibody for early Alzheimer's disease. The weekly self-injection regimen reduces treatment burden compared to intravenous administration, potentially increasing uptake among the estimated 17 million Chinese patients with mild cognitive impairment or mild dementia.
FibroBiologics received a U.S. patent for a topical wound therapy using 3D fibroblast spheroids and fibroblast-derived materials, with preclinical evidence showing accelerated healing in diabetic and non-diabetic wound models. This approach addresses chronic wounds—a significant driver of morbidity and cost—by leveraging the regenerative capacity of fibroblast-derived signaling molecules rather than the cells themselves.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
Tim Maupin's film explores the ethical and personal dimensions of rejuvenation technology arriving before universal access, examining what happens when life-extension therapies can save some but not others. The narrative anchors longevity science in the lived human experience of aging parents and the institutional barriers that determine who benefits from breakthrough interventions.
Veradermics has secured $820 million in funding to advance VDPHL01, an oral extended-release formulation of minoxidil designed to treat pattern hair loss in men and women. The company reports positive Phase 2 data in women and plans confirmatory Phase 3 readouts in men by late 2026, positioning itself to become the first FDA-approved oral, non-hormonal hair loss treatment.
Annovis Bio exceeded enrollment targets for its Phase 3 trial of buntanetap, recruiting 850 patients against a goal of 760 for early Alzheimer's disease. The achievement demonstrates patient demand for novel therapeutics, though the drug's efficacy and regulatory approval remain unproven and contingent on data expected in early 2027.
LifespanningRx released the Peptide Explorer, a structured digital questionnaire that maps health goals across ten domains and flags potential peptide therapy candidates for clinician review. The tool screens responses against safety criteria before recommending further evaluation, positioning peptide therapy within a clinician-supervised framework rather than direct-to-consumer access.
Minicircle, a gene therapy company, advanced to the XPRIZE Healthspan finals with a non-viral circular DNA platform designed to address multiple aging phenotypes simultaneously—muscle decline, neuroinflammation, mitochondrial dysfunction, and immune dysregulation—in adults aged 50 to 80. The $1 million award will fund a placebo-controlled human trial to measure rejuvenation endpoints, representing a shift toward measurable, multisystem interventions in aging.
Senescent cells accumulate in aging kidneys alongside localized immune cell infiltration, with macrophages clustering preferentially around senescent tubular cells. Senolytic treatment reduces senescent cell burden and overall immune infiltration, though macrophages persist near residual senescent structures, suggesting incomplete resolution of senescence-associated inflammatory niches.